PRESS RELEASE NEW YORK—-Bristol-Myers Squibb Company today announced that it has completed the previously announced prepared acquisition of Flexus Biosciences, Inc buy priligy dapoxetine online http://priligyreview.net . The purchase includes full rights to F001287, Flexus’ lead preclinical, small-molecule IDO1-inhibitor targeted for IND filing in the second half of 2015 and an IDO/TDO discovery system which includes its IDO-selective, IDO/TDO TDO-selective and dual substance libraries. A recently formed entity founded by the current shareholders of Flexus will retain, from and following the closing, all non-IDO/TDO resources of Flexus including those related to Flexus’ Phase 1 FLT3 and CDK4/6 inhibitor, its earlier stage small-molecule Treg cancer immunotherapy programs, and its own current facilities and personnel..

http://www.priligyreview.net/

Bristol-Myers Samsung and Squibb BioLogics announce biopharmaceutical production relationship Bristol-Myers Squibb Firm and Samsung BioLogics today announced the firms have entered right into a 10-yr agreement under which Samsung BioLogics will manufacture a commercial antibody cancer medication for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea. Financial terms were not disclosed. In July 2013 and commercial creation will immediately begin following regulatory approvals Technology transfer and trial creation will commence. ‘We are very happy to announce this strategic making relationship with Bristol-Myers Squibb and appearance ahead to delivering best-in-class manufacturing solutions with the best global quality specifications,’ said Tae-Han Kim, president and CEO of Samsung BioLogics.